未登录

Y

Yuanmei Zhu

Chinese Academy of Medical Sciences and Peking Union Medical College

H指数:21

被引数:1,287

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

An HIV fusion-inhibitory lipopeptide provides robust post-exposure prophylaxis and prevents viral reservoir seeding in macaques

一种HIV融合抑制性脂肽可提供强效的暴露后预防，并阻止病毒储存库在食蟹猴中的建立

IF6.9

2025-09-050

OAAI

Addition of a short HIV-1 fusion-inhibitory peptide to PRO 140 antibody dramatically increases its antiviral breadth and potency

JOURNAL OF VIROLOGY

IF3.8

2025-03-010

OAAI

Susceptibility and Resistance of SARS-CoV-2 Variants to LCB1 and Its Multivalent Derivatives

IF3.5

2023-12-250

OAAI

Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein

JOURNAL OF VIROLOGY

IF3.8

2023-08-311

OA

Resistance profile and mechanism of severe acute respiratory syndrome coronavirus-2 variants to LCB1 inhibitor targeting the spike receptor-binding motif

FRONTIERS IN MICROBIOLOGY

IF4.5

2022-10-117

OAAI

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron

SARS-CoV-2融合抑制性脂肽对包括Omicron在内的关注的不同变体保持高效力

EMERGING MICROBES & INFECTIONS

IF7.5

2022-07-2111

OAAI

Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy

EMERGING MICROBES & INFECTIONS

IF7.5

2021-12-216

OAAI

Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants

EMERGING MICROBES & INFECTIONS

IF7.5

2021-06-1823

OAAI

Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus

EMERGING MICROBES & INFECTIONS

IF7.5

2021-04-2918

OAAI

Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals

SCIENCE ADVANCES

IF12.5

2020-11-0663

OAAI

Therapeutic Efficacy and Resistance Selection of a Lipopeptide Fusion Inhibitor in Simian Immunodeficiency Virus-Infected Rhesus Macaques

JOURNAL OF VIROLOGY

IF3.8

2020-07-164

OAAI

Preparation and evaluation of amphipathic lipopeptide-loaded PLGA microspheres as sustained-release system for AIDS prevention

ENGINEERING IN LIFE SCIENCES

IF3

2020-07-1219

OAAI

Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity

JOURNAL OF VIROLOGY

IF3.8

2020-07-01175

OAAI

Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors

IF3.5

2020-03-182

OAAI

The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors

JOURNAL OF VIROLOGY

IF3.8

2019-12-128

OA

A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus

JOURNAL OF VIROLOGY

IF3.8

2019-11-1522

OAAI

Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors

IF3.5

2019-07-037

OAAI

Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity

JOURNAL OF VIROLOGY

IF3.8

2019-06-0137

OAAI

Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques

IF4.9

2019-02-0441

OAAI

Structural and functional characterization of HIV-1 cell fusion inhibitor T20

IF3.1

2019-01-0237

PREAI